XML 27 R16.htm IDEA: XBRL DOCUMENT v3.25.2
Equity Incentive Plans and Warrants
6 Months Ended
Jun. 30, 2025
Equity Incentive Plans and Warrants [Abstract]  
Equity Incentive Plans and Warrants
(10)
Equity Incentive Plans and Warrants
 
Stock-Based Awards
 
(a)
Stock Option Plans
 
Activity under the Company’s stock option plans for the six months ended June 30, 2025 was as follows:
 
             
      Number of options      Weighted
average
exercise
price
     Aggregate
Intrinsic Value
 
Outstanding at December 31, 2024
   2,974,219   $ 1.60       
    Granted
   1,595,315     1.09       
    Forfeited
   (171,037    1.10       
Outstanding at June 30, 2025
   4,398,497   $ 1.43  
619,562 
                   
 Vested and exercisable at June 30, 2025    1,796,098   $ 2.01  
380,874 
 
The intrinsic value represents the amount by which the market price of the underlying stock at June 30, 2025 exceeds the exercise price of an option.
 
Options granted under the 2021 Stock Option Plan for the six months ended June 30, 2025 to employees and nonemployees were 1,524,915 and 70,400, respectively and the weighted average exercise prices were $1.09 and $0.98, respectively. The weighted average fair values of the options granted to employees and nonemployees were $0.84 and $0.73, respectively and were estimated using the following Black-Scholes assumptions:
 
         
      Employees      Nonemployees 
Expected term (in years)
   6.06     5.50 
Risk‑free interest rate
   4.37%    3.91%
Dividend yield
   %     — %
Expected volatility
   91.17%    90.77%
 
No options were exercised for the six months ended June 30, 2025 under our stock option plans.
 
On June 25, 2025, Femasys stockholders approved an amendment to the 2021 Equity Incentive Plan to increase the total number of shares of common stock authorized for issuance by 3,000,000. As of June 30, 2025, the total number of shares of common stock reserved for future awards under the 2021 Stock Option Plan was 3,133,620.
 
(b)
Inducement Grants
 
Since 2023, the Company has granted 250,000 inducement grants, a stock option grant to certain employees for the right to purchase shares, which were approved by the Compensation Committee. The inducement grants vest in equal installments over four years provided the employee remains employed by the Company on the vesting date. In the first quarter of 2025, there were forfeitures of 100,000 options. In the second quarter of 2025, there was a grant of 100,000 options.
The inducement grants are summarized as follows:
 
   
Number of
options
     
Weighted
average
exercise
price
     
Weighted
average
remaining
life years
 
Outstanding at December 31, 2024
 250,000 
$1.89     8.07 
    Granted  100,000     0.90     9.98 
    Forfeited
 (100,000    1.10      
Outstanding at June 30, 2025
 250,000 
$1.81     8.11 
                 
Vested and exercisable at June 30, 2025
 100,000 
$2.56     6.82 
 
(c)
Share-Based Compensation Expense
 
The following table shows the share-based compensation expense related to vested stock option grants to employees and nonemployees by financial statement line item on the accompanying condensed statements of comprehensive loss:
 
                        
    Three Months Ended June 30,   Six Months Ended June 30,
    2025       2024       2025       2024  
Research and development
$ 68,299     34,629     205,223     64,637 
Sales and marketing
  21,418     18,246     10,987     24,764 
General and administrative
  92,254     51,138     332,998     92,197 
Total share-based compensation expense
$ 181,971     104,013     549,208     181,598 
 
As of June 30, 2025, the remaining share-based compensation expense that is expected to be recognized in future periods for employees and nonemployees is $1,924,030, which includes $155,222 of compensation expense to be recognized upon achieving certain performance conditions. For service-based awards, the $1,768,808 of unrecognized expense is expected to be recognized over a weighted average period of 2.9 years.
 
(d)
Employee Stock Purchase Plan (ESPP)
 
For the six months ended June 30, 2025, 49,247 shares of common stock were issued under the Company’s ESPP at a fair value of $40,875. For the six months ended June 30, 2024, 12,081 shares of common stock were issued under the Company’s ESPP Plan at a fair value of $10,390. As of June 30, 2025, the total number of shares of common stock reserved for future awards under the ESPP was 719,668.